Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures FTSE (0.09%), DAX (0.16%), CAC40 (0.07%)

Dec 22 ,2025

  • Synopsis

    • European equity markets are set for a lower open amidst Asia equities higher across the board Monday. Tech-dominated benchmarks in Japan, South Korea and Taiwan outperforming; Shenzhen and Shanghai also trading higher, Hong Kong trading only a few points higher. India trading higher, Southeast Asia also seeing modest gains. US futures trading higher.

    • Focus on Ukraine peace talks in Florida as US special envoy Steve Witkoff said Trump administration officials held productive and constructive meetings with Ukrainian and European counterparts. Topics discussed included further developing the existing 20-point plan, a US security guarantee framework and the economic development plan for Ukraine. Separate talks have been taking place in Miami between the US and the Russian envoy, Kirill Dmitriev. French presidency said they welcome Russia's readiness to engage in dialogue with Macron and says will decide in the coming days on the best way to proceed.

    • Macro data include UK Q3 final GDP, Italy Nov PPI, Spain Oct trade balance, Denmark Q3 final GDP, Norway Nov unemployment rate, Finland Nov PPI, Ireland Nov PPI

    • A light corporate front sees Duerr (DUE.GR) raising FY25 forecast for free cash flow to €100-200M from prior €0-50M whilst Theon International (THEON.NA) reported prelim FY25 order-intake during the year of more than 3x expected 2025 revenue versus original guidance of c.2x.. Mutares (MUX.GR) will acquire Wärtsilä's (WRT1V.FH) Gas Solutions business and Biologics to acquire Human Genome Sciences from GSK (GSK.LN) for KRW413.62B/£209.5M.

    • CMD/events taking place today include, Pantheon Resources (PANR.LN) business update call, Bambuser (BUSER.SS) 1:30 reverse stock split, Vivesto (VIVO.SS) EGM in connection with previously disclosed rights issue.

  • Politics/Macro/World News

    • Paris welcomes Putin's 'readiness' for bilateral talks with Macron - Politico

    • Kremlin says chances of peace not improved by European and Ukrainian changes to US proposals - Reuters

    • US, Ukraine Held 'Constructive' Talks in Florida, Witkoff Says - Bloomberg

    • Streeting urges closer trading ties with Europe to grow UK economy - Guardian

    • Finland Nov PPI +0.2% vs consensus (0.1%) and prior +0.2%

  • Top company news

    • Earnings/updates

      • THEON.NA (Theon International) -- reports prelim FY25 order-intake during the year of more than 3x expected 2025 revenue versus original guidance of c.2x

      • DUE.GR (Duerr) -- Dürr AG raises FY25 forecast for free cash flow to €100-€200M from €0-€50M prior

    • M&A

      • EQT.SS (EQT) -- to acquire 100% of A-Train

      • WRT1V.FH (Wärtsilä) -- Mutares SE & Co KGaA to acquire Wärtsilä's Gas Solutions business; terms undisclosed

      • GSK.LN (GSK Plc) -- Samsung Biologics to acquire Human Genome Sciences from GSK for KRW413.62B/£209.5M

      • RANA.NO (Rana Gruber) -- Champion Iron enters into agreement to acquire Rana Gruber at NOK79 (A$11.8) per share cash

      • DEMANT.DC (Demant) -- to sell EPOS to Acco Brands for €7M (DKK50M/$8.2M) in cash up front

      • WTB.LN (Whitbread) -- Corvex likely to push for Whitbread to split itself - Sunday Times

      • ICAD.FP (Icade) --

        • completes sale of the Le Mauvin business park to Sogaris for €69M

        • signs preliminary agreement to sell Marignan building on the Champs-Élysées for €402M

      • UN0.GR (Uniper) -- German government passes law clearing Uniper to resume dividends -- Reuters

      • ARISE.SS (Arise) -- acquires 10 MW wind farm in SE2

      • ENDUR.NO (Endur ASA) -- Repstad Anlegg AS - Endúr ASA subsidiary - to acquire Kragerø Sjøtjenester in deal worth ~NOK 63M (EV basis)

      • HSG to acquire majority stake in Golden Goose; terms undisclosed (19-Dec, post EU close)

    • Healthcare

      • IPN.FP (Ipsen Pharma) -- Simcere Pharmaceutical Group subsidiary signs exclusive licensing agreement with Ipsen Pharma

      • NOVN.SW (Novartis) --

        • FDA grants orphan drug designation to iptacopan (Fabhalta) for myasthenia gravis

        • and US government reach agreement on lowering drug prices in the US

      • SAN.FP (Sanofi) -- reaches agreement with US government to lower medicine costs

      • ROG.SW (Roche Holding) --

        • Genentech announces agreement with U.S. government that lowers costs for state Medicaid programs

        • Roche CEO: Drug deals with Trump administration mean prices will rise in Switzerland - Tages-Anzeiger

        • FDA approves Roche's Lunsumio VELO for subcutaneous use in relapsed or refractory follicular lymphoma

      • CYTK (Cytokinetics) -- announces FDA approval of MYQORZO (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic Cardiomyopathy

      • MIRM (Mirum Pharmaceuticals) -- filed patent infringement suits against ANDA Filers - 8-K

      • DBV.FP (DBV Technologies) -- SEC filing: SCHEDULE 13D/A (Filed by Bpifrance Participations SA)

      • NYXH.BB (Nyxoah) -- announces issuance of first tranche of convertible bonds

      • HNSA.SS (Hansa Biopharma) -- Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation

      • SIGHT.FP (GenSight Biologics) -- Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ in France

      • +BOEHRINGER (Boehringer Ingelheim) -- FDA approves label expansion for Jascayd in progressive pulmonary fibrosis (18-Dec)

      • +BOEHRINGER (Boehringer Ingelheim) -- announces broad agreement with the U.S. Government to lower the cost of medicines for American patients and expand its U.S. footprint

      • FYB.GR (Formycon) -- FDA approves Nufymco (ranibizumab-leyk)

    • Other

      • DOFG.NO (DOF Group) -- updates on project awards in the Atlantic region and contract award in the North America region

      • SKA.B.SS (Skanska) -- to widen expressway in San Jacinto, California (USA_ for $107M, about SEK 1.1B

      • EDPR.PL (EDP Renovaveis) -- secures a 15-year PPA with a large global technology company in the US

      • AKZA.NA (Akzo Nobel) -- CFO Maarten de Vries to extend tenure for one year

      • RHM.GR (Rheinmetall) -- receives order for RCH155 wheeled howitzer through Artec JV; total order value ~€1.2B

      • TIT.IM (Telecom Italia) --

        • announces favorable final ruling of the Court of Cassation concerning the 1998 License Fee dispute

        • board to discuss converting savings shares into ordinary shares - Bloomberg

        • calls shareholder meeting on 28-Jan to vote on conversion of savings shares into ordinary shares

      • SPM.IM (Saipem) -- awarded offshore EPCI contract from QatarEnergy LNG worth $3.1B (~€2.7B)

      • MOWI.NO (Mowi) -- enters strategic and industrial partnership agreement with Skretting/Nutreco; strategic partnership to deliver more than NOK 650M (€55M) in annualised net cost savings

      • CLN.SW (Clariant) -- rejects allegations from MOL Group and Braskem against four companies related to the 2020 competition law infringement

      • TGS.NO (TGS-NOPEC Geophysical Co.) -- announces multi-year enterprise licensing agreement with a supermajor for Imaging AnyWare

      • Estimated weekend box office revenues in US, Canada $176.2M, +23.8% y/y - Box Office Mojo

      • Polestar announces equity financing transaction of $300M, separate $300M debt to equity conversion

      • States sue to restore EV charging funds and UPS faces wage theft claims in NY in litigation developments (19-Dec)

  • Key ratings changes

    • Upgrades

      • NCH2.GR (thyssenkrupp nucera) -- neutral from underperform at Santander

  • Data

    • Nikkei +1.81% to 50402.39

    • Hang Seng (0.02%) to 25685.68

    • Shanghai Composite +0.66% to 3916.28

    • S&P futures +19.0 vs prior close of 6887.3

    • €-$ (0.0002) or (0.02%) to 1.1718

    • $-¥ (0.28) or (0.18%) to 157.33

    • €-¥ (0.38) or (0.21%) to 184.34

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE